O
SRPT icon

Ossiam’s Sarepta Therapeutics SRPT Stock Holding History

Ossiam’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-98
Closed -$11.9K – 650
2024
Q4 		$11.9K Buy
98
+16
+20% +$1.96K ﹤0.01% 610
2024
Q3 		$10.2K Buy
+82
New +$11.3K ﹤0.01% 621
2024
Q1 		– Sell
-1,373
Closed -$132K – 678
2023
Q4 		$132K Hold
1,373
– – ﹤0.01% 612
2023
Q3 		$166K Sell
1,373
-195
-12% -$22K ﹤0.01% 613
2023
Q2 		$180K Buy
1,568
+803
+105% +$104K ﹤0.01% 619
2023
Q1 		$105K Buy
+765
New +$99.2K ﹤0.01% 599

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Ossiam's SRPT Position: Q1 2025 in Review

Ossiam sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 98 shares — an estimated $11.9K sold.

Ossiam first reported a position in SRPT in Q1 2023 and held it in 6 quarters. The position peaked at $180K in Q2 2023. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Ossiam reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ossiam sold 98 Sarepta Therapeutics shares in Q1 2025, an estimated $11.9K.
  • Ossiam first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 6 quarters.
  • Ossiam's Sarepta Therapeutics position peaked at $180K in Q2 2023.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Ossiam's 13F filing for Q1 2025, filed 14 May 2025.